Responses
Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.